Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
16 Dec 2024
// BUSINESSWIRE
03 Dec 2024
// BUSINESSWIRE
07 Nov 2024
// BUSINESSWIRE
05 Nov 2024
// BUSINESSWIRE
28 Oct 2024
// BUSINESSWIRE
15 Oct 2024
// BUSINESSWIRE
Details:
The net proceeds from the offering will be used to fund THIO-101 (6-Thio-2-Deoxyguanosine), which is currently undergoing mid-stage trials for the treatment of non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $2.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 28, 2024
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $2.4 million
Deal Type : Private Placement
MAIA Biotechnology Announces $2.44 Million Private Placement
Details : The net proceeds from the offering will be used to fund THIO-101 (6-Thio-2-Deoxyguanosine), which is currently undergoing mid-stage trials for the treatment of non-small cell lung cancer.
Brand Name : THIO-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 28, 2024
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2024
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MAIA Reports Positive Updates in Phase 2 Study of THIO for Non-Small Cell Lung Cancer
Details : THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer.
Brand Name : THIO-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 10, 2024
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2024
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MAIA: THIO Shows Strong Efficacy in Non-Small Cell Lung Cancer
Details : THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer.
Brand Name : THIO-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 04, 2024
Details:
The Company intends to use the net proceeds from the offering for to fund research and development activities, such as THIO-101 (6-Thio-2-Deoxyguanosine) for patients with non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 23, 2024
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $1.0 million
Deal Type : Private Placement
MAIA Biotechnology Announces $1.00 Million Private Placement
Details : The Company intends to use the net proceeds from the offering for to fund research and development activities, such as THIO-101 (6-Thio-2-Deoxyguanosine) for patients with non-small cell lung cancer.
Brand Name : THIO-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 23, 2024
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is in clinical development with cemiplimab for non-small cell lung cancer, targeting telomeres to overcome cancer cell resistance.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MAIA Biotechnology Announces Strong Efficacy Of THIO for Lung Cancer Patients
Details : THIO-101 (6-Thio-2-Deoxyguanosine) is in clinical development with cemiplimab for non-small cell lung cancer, targeting telomeres to overcome cancer cell resistance.
Brand Name : THIO-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 06, 2024
Details:
THIO (6-thio-dG) is a first-in-class telomere-targeting agent being evaluated in combination with Libtayo (cemiplimab) for advanced non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MAIA Completes Enrollment in THIO-101 Phase 2 Trial for Lung Cancer
Details : THIO (6-thio-dG) is a first-in-class telomere-targeting agent being evaluated in combination with Libtayo (cemiplimab) for advanced non-small cell lung cancer.
Brand Name : THIO
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2024
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in phase 2 trials in combination with Libtayo for non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MAIA Biotechnology Provides Updates for Anticancer Agent and Targeted Milestones
Details : THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in phase 2 trials in combination with Libtayo for non-small cell lung cancer.
Brand Name : THIO
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2024
Details:
THIO (6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development in combination with Libtayo (cemiplimab) to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : THIO (6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development in combination with Libtayo (cemiplimab) to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Brand Name : THIO-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2023
Details:
MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2023
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : H.C. Wainwright & Co.
Deal Size : $4.0 million
Deal Type : Public Offering
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
Details : MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune c...
Brand Name : THIO
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 17, 2023
Details:
MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 15, 2023
Lead Product(s) : 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : H.C. Wainwright & Co.
Deal Size : $4.0 million
Deal Type : Public Offering
MAIA Biotechnology Announces $4 Million Registered Direct Offering
Details : MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune c...
Brand Name : THIO-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?